E. Lynne Kelley, M.D. Tenders Her Resignation as the Chief Medical Officer of X4 Pharmaceuticals, Inc., Effective April 3, 2020
March 20, 2020 at 04:08 pm
Share
On March 18, 2020, E. Lynne Kelley, M.D. tendered her resignation, effective April 3, 2020, as the Chief Medical Officer of X4 Pharmaceuticals, Inc., to pursue other business opportunities. Dr. Kelley will be a named executive officer of the company for fiscal 2019.
X4 Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4, that is being developed as an oral, once-daily therapy. It has developed a pipeline of small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). It has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
X4 PHARMACEUTICALS, INC. 
